Addex Therapeutics Ltd.ADXNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative allosteric modulator therapies for underserved neurological and psychiatric disorders. It operates in global biopharmaceutical markets, with a pipeline targeting rare and common central nervous system conditions to address unmet patient needs.
ADXN Q3 FY2025 Key Financial Metrics
Revenue
$33.0K
Gross Profit
N/A
Operating Profit
$-765.6K
Net Profit
$-1.7M
Gross Margin
N/A
Operating Margin
-2320.0%
Net Margin
-5256.7%
YoY Growth
N/A
Addex Therapeutics Ltd. Q3 FY2025 Financial Summary
Addex Therapeutics Ltd. reported revenue of $33.0K for Q3 FY2025, with a net profit of $-1.7M (-5256.7% margin).
Key Financial Metrics
| Total Revenue | $33.0K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | N/A |
| Operating Margin | -2320.0% |
| Report Period | Q3 FY2025 |
Income Statement
| Q3 2025 | |
|---|---|
| Revenue | $33000 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2025 | |
|---|---|
| Assets | N/A |
| Liabilities | N/A |
| Equity | N/A |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $-1707 |